

GRAND VENTURE TECHNOLOGY LIMITED

(Incorporated in the Republic of Singapore) (Company Registration No.: 201222831E)

ANNOUNCEMENT

BUSINESS UPDATE FOR 1Q25

The Board of Directors (the "Board") of Grand Venture Technology Limited (the "Company" and together with its subsidiaries, the "Group") wishes to provide a voluntary update on the Group's business and financial performance for the three months ended 31 March 2025 ("1Q25"). The comparative financial quarter was for the three months ended 31 March 2024 ("1Q24").

Glossary of abbreviations

XQ25: Financial quarter ended 31 March (1Q), 30 June, 30 September, and 31 December 2025, respectively XQ24: Financial quarter ended 31 March (1Q), 30 June, 30 September, and 31 December 2024, respectively


EBITDA: Earnings before Interest, Tax, Depreciation and Amortisation

i.e. Profit before Tax + Interest cost - Interest income + Depreciation + Amortisation

Financial summary

| S\$'000 | 1Q25 | 1Q24 | yoy% |
|------------------------------|--------|--------|-------|
| Revenue | 44,626 | 30,809 | 44.8% |
| Gross profit | 11,135 | 7,936 | 40.3% |
| EBITDA | 8,354 | 6,475 | 29.0% |
| EBITDA (Adjusted against FX) | 8,772 | 5,918 | 48.2% |
| Net profit after tax | 2,592 | 2,029 | 27.7% |
| | | | |
| Cycle wastit manyoin | 25.00/ | 05.00/ | |

| Gross profit margin | 25.0% | 25.8% | |
|------------------------|-------|-------|--|
| EBITDA margin | 18.7% | 21.0% | |
| Adjusted EBITDA margin | 19.7% | 19.2% | |
| Net profit margin | 5.8% | 6.6% | |



| S\$'000 | 1Q24 | 2Q24 | 3Q24 | 4Q24* | 1Q25 |
|----------------------|--------|--------|--------|--------|--------|
| Revenue | 30,809 | 37,500 | 43,546 | 47,660 | 44,626 |
| Gross profit | 7,936 | 10,072 | 11,489 | 9,521 | 11,135 |
| EBITDA | 6,475 | 7,438 | 5,701 | 9,229 | 8,354 |
| Net profit after tax | 2,029 | 2,279 | 2,000 | 4,780 | 2,592 |
| Gross profit margin | 25.8% | 26.9% | 26.4% | 20.0% | 25.0% |
| EBITDA margin | 21.0% | 19.8% | 13.1% | 19.4% | 18.7% |

*Gross profit in 4Q24 included one-time expenses such as sales rebates, inventory provisions and written off and reclassification of expenses. Adjusting against these expenses and reclassifications, gross margins was 23.9%.


On the back of a 44.8% year-on-year increase in revenue to S\$44.6 million, from S\$30.8 million in 1Q24, the Group recorded a 29.0% rise in EBITDA to S\$8.4 million, and 27.7% growth in net profit after tax to S\$2.6 million. These improvements were driven by continued wallet share expansion with its key customers.

Gross profit margin was relatively stable in 1Q25, with continued ongoing absorption of expanded capacities and capabilities in preparation for future growth.

EBITDA in 1Q25 had included a foreign exchange loss of S\$0.4 million, whilst EBITDA in 1Q24 had included a foreign exchange gain of S\$0.5 million. Adjusting against the foreign exchange gain/loss, EBITDA margins in 1Q25 and 1Q24 were 19.7% and 19.2% respectively.

Revenue summary by segments

| | 1Q25 | % | 1Q24 | % | Growth% |
|--|---------|--------|---------|--------|---------|
| | S\$'000 | | S\$'000 | | |
| Semiconductor | 25,558 | 57.3% | 15,742 | 51.1% | 62.4% |
| Life sciences | 6,340 | 14.2% | 4,953 | 16.1% | 28.0% |
| Electronics, Aerospace, Medical and Others | 12,728 | 28.5% | 10,114 | 32.8% | 25.8% |
| Total | 44,626 | 100.0% | 30,809 | 100.0% | 44.8% |



Semiconductor

Revenue from the Semiconductor segment rose significantly in 1Q25, increasing by 62.4% to S\$25.6 million compared to \$15.7 million in 1Q24. This robust growth was primarily driven by a year-on-year growth in demand for the company's test equipment-related products, including High Bandwidth Memory ("**HBM**") testers. In addition, there was progressive contributions from its new front-end semiconductor customers that further expanded the revenue base.

Life sciences

The Life Sciences segment recorded a 28.0% year-on-year increase in 1Q25, achieving S\$6.3 million compared to S\$5.0 million in 1Q24. This was fuelled by continued wallet share growth with existing customers, where we are benefiting from more products being shifted to Asia. Additionally, this segment benefited from contributions from a newly onboarded customer in the automated sample preparation equipment space.

Electronics, Aerospace, Medical and Others

Revenue from the Electronics, Aerospace, Medical and Others segments increased 25.8% in 1Q25, reaching S\$12.7 million compared to S\$10.1 million in 1Q24. This took into account S\$3.1 million contribution by newly onboarded subsidiary – ACP Metal Finishing Pte. Ltd., offset by weakness in the electronics segment.

Outlook

The semiconductor industry has faced a series of disruptions over the past few years – from COVID-19, followed by inventory digestion, a prolonged downturn for legacy nodes and mainstream equipment, and finally, the tariffs present volatility. However, amidst this volatility, Artificial Intelligence ("AI") and High-Performance Computing ("HPC") have emerged as long-term structural growth drivers. Early-stage adoption is already driving significant demand, and we expect this momentum to continue accelerating.

The surge in AI and HPC is translating into an increased need for HBM, which in turn is accelerating the adoption of advanced packaging technologies such as Thermal Compression Bonding ("TCB") and Hybrid Bonding ("HB") as well as Through Silicon-Via ("TSV"). GVT is already actively engaged with leading blue-chip customers across all these technologies, positioning us at the forefront of this structural shift and the associated long-term tailwinds. These engagements have already translated into new program wins in TCB, TSV and HB, allowing the group to start 2025 on a robust growth trajectory. As AI and HPC adoption continues to scale across industries, GVT is well poised to deepen our role in the customers' value chain, unlocking substantial multi-year growth opportunities.

In addition, GVT expects gradual but resilient recovery for legacy nodes in late 2025, with momentum anticipated to strengthen in 2026. Given that we have already achieved record performance despite the slowdown in legacy nodes and broader back-end semiconductor market, this recovery presents meaningful upside opportunity within the semiconductor segment.

Beyond semiconductors, the Group expects resilient demand from life sciences customers supported by continued wallet share gain. GVT is deepening our value proposition for the aerospace sector in China, by expanding our services to include annealing and non-destructive testing, strengthening our competitive advantage and value-add to customers.

GVT continues to closely monitor the evolving macroeconomic landscape, including recent tariff developments. As per our latest update, the Group anticipated limited exposure to tariff measures, with less than 10% of FY24 revenue derived from US exports – over 70% which originate from Singapore that enjoys the lowest applicable tariffs albeit the 90-day pause. Most of GVT's products support customer programs focused on Asia and Europe, which limited exposure to US endmarkets. The Group is actively working with customer to mitigate potential disruptions or cost impacts. The company is actively working with customers to redirect US shipments to Asia, on top of a portion being low-volume New Product Introduction ("NPI") that are transitioning to regional production.

The above dynamics not only mitigate tariff impact but also open up strategic opportunities, as customers increasingly seek proven and agile partners in Asia. This will benefit GVT with its strategic footprint, accomplished track record, scalable capacity and deep engineering capabilities. We anticipate an acceleration of NPI qualification with US programs targeted for Asia or EU markets, which the Group being a strong position to capitalise. Additionally, there is a growing number of multinational companies expanding in China to serve the local market, strengthening the prospects and opportunities for our China operations.

The Group reiterates its confidence in achieving the target revenue guidance (25 February 2025) between S\$90 million and S\$96 million for the financial period ending 30 June 2025.

BY ORDER OF THE BOARD

LEE TIAM NAM

Executive Deputy Chairman 3 June 2025